COPENHAGEN, Denmark, December 13 /PRNewswire/ --

- Summary: Genmab has Announced Details of a Planned Phase II Study of Ofatumumab to Treat Relapsing Remitting Multiple Sclerosis

Genmab A/S (OMX: GEN) announced today details of a planned Phase II study of ofatumumab (HuMax-CD20(R)) for the treatment of relapsing remitting multiple sclerosis (RRMS). Approximately 324 patients will be enrolled in the study which will be conducted under Genmab's collaboration with GlaxoSmithKline (GSK). The study is expected to begin in the first quarter of 2008.

REHOVOT, Israel and NEW YORK, December 13 /PRNewswire/ --

- Target Diseases for This Collaboration are Diffuse Large Cell Lymphoma, Transformed Follicular Lymphoma, and Chronic Lymphocytic Leukemia

- Collaboration to Develop MicroRNA-Based Diagnostics Test, Early Detection and Prognosis.

- 43,000 People Will be Diagnosed With These Types of Cancers in 2007 in the US Alone(1)

- MicroRNAs Hold Significant Potential as Highly Sensitive and Specific Biomarkers for Hematological Cancers

- Collaboration Also Will Seek to Identify MicroRNA (miRNA) Targets for Therapeutic Applications

Researchers at Low Temperature Laboratory and Laboratory of Physics (TKK) and at University of Stony Brook (New York) have potentially solved the problem of accurately defining the ampere. The group has developed a frequency to current converter, the accuracy of which is based on the known charge of an electron and the extreme accuracy in defining frequency. The nanodevice is essentially a single electron transistor which works as a simple single-electron turnstile. Its best performance is achieved at very low temperatures.

Previously, the electric current and its unit, the ampere, have been defined through the classical force induced to two parallel leads carrying the current.

CALGARY, Canada, December 13 /PRNewswire/ -- SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that Oye Olukotun, MD, MPH, FACC, FAHA, has agreed to join the Board of Directors of the Company. Dr. Olukotun is the co-founder and Chief Medical Officer of VIA Pharmacueticals (NASDAQ: VIAP) a company focused on cardiovascular disease treatments. He will replace Dr. Douglass Given, who is retiring from the Board of SemBioSys after serving for seven years.

LONDON, December 13 /PRNewswire/ --

- Germany is lagging in seasonal online retail shopping

comScore, Inc. (Nasdaq: SCOR), a leader in measuring the digital world, today released the second in a series of three studies of the online shopping activity of U.K., French and German consumers this Christmas season. This study tracked the number of visits to online retail sites each week since October 29, using data collected from the comScore World Metrix audience measurement service.

Online Retail Site Visits Increase in November

HOUSTON, December 13 /PRNewswire/ --

Endeavour International Corporation (Amex: END) announced today that the company will host a conference call at 11:00 a.m. Eastern Standard Time (16:00 Greenwich Mean Time) on Wednesday, December 19, 2007 to discuss the company's 2008 capital budget and guidance.

To participate and ask questions during the conference call, dial +1-888-204-4317 (U.S., toll-free) or +1-913-312-1457 (international), pass code: 4398087. To listen only to the live audio web cast via the Internet access Endeavour's internet home page at http://www.endeavourcorp.com.

Their day job is to keep trees upright but the forest's tiniest building blocks could soon be on their way into future products. Imagine a packaging material that also kills bacteria. Or a disposable duvet cover that keeps infection away when you are in a hospital bed.

Scientists in Trondheim believe that exciting new products can be created if we make use of some of nature's tiniest construction materials. They are called “fibrils” and you may never have heard of them, but there are millions of them in each piece of paper you hold.

A wonder of nature

Fibrils form continuously in all growing trees.

GENEVA, Switzerland, December 13 /PRNewswire/ --

- Merck Serono Will Fund a US$2 Million Initiative to Drive Treatments for Parkinson's Disease-Related Cognitive Dysfunction and Mood Disorders

Merck Serono, a division of Merck KGaA of Darmstadt, Germany, is supporting the US$2-million commitment of The Michael J. Fox Foundation for Parkinson's Research (MJFF) for research toward therapies to alleviate Parkinson's disease (PD)-related cognitive dysfunction and mood disorders. The funding is to be awarded under a new initiative, Cognitive Deficits and Mood Disorders in Parkinson's Disease.

MALVERN, Pennsylvania, December 13 /PRNewswire/ --

- Solstice Neurosciences, Inc. Launches a Self-Guided Lesson as Prep for In-Person Workshops

In recognition that physician comfort and knowledge with techniques around botulinum toxin injections lead to the best results for patients with cervical dystonia (CD), Solstice Neurosciences, Inc. (Solstice) has created MYOBLOC(TM) University, an online, self-study resource that incorporates new learning technology. The course integrates multi-dimensional, life-like animation throughout the content -- with anatomy based on real patients with CD and actual injection technique demonstrations with Myobloc(R) (Botulinum Toxin Type B) Injectable Solution. The course can be accessed at www.myoblocuniversity.com.